Abstract
Introduction
The long-term clinical outcomes of patients with metastatic renal cell carcinoma (mRCC)
and a complete response (CR) to the tyrosine kinase inhibitor (TKI) sunitinib are
poorly known. The characteristics of these patients could reveal previously undetected
associations with clinical variables.
Patients and Methods
This observational, retrospective study (ATILA) used data from a registry of patients
with mRCC who had received first-line sunitinib and had achieved CR from 2007 to 2018
in Spain.
Results
Sixty-two patients with CR were included; 48 patients (77.4%) received sunitinib in
monotherapy and 14 (22.6%) combined with or followed by local treatment. Median age
was 58.5 years (range, 32–81). Most patients (79.0%) had clear cell histology and
had undergone previous nephrectomy (90.3%). The majority (70.2%) had an intermediate
IMDC prognosis, 23% favorable and 7.0% poor. The median time on treatment with sunitinib
was 28.2 months (IQR, 16.7–41.0) and the median time to CR was 10.9 months (IQR, 7.2–19.3).
After a median follow-up of 8 years (range, 3–13 years), the median PFS was not reached.
The overall median duration of complete response was 64.1 months (IQR, 32.2–99.4).
The tolerance and safety profile of sunitinib was consistent with previous reports.
Conclusion
Durable CR to sunitinib was observed in patients regardless the prognosis group, metastasis
site or histology type, with 75% of patients remaining in CR after 10 years. Clinicaltrials.gov:
NCT03916458.
Keywords
To read this article in full you will need to make a payment
Purchase one-time access:
Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online accessOne-time access price info
- For academic or personal research use, select 'Academic and Personal'
- For corporate R&D use, select 'Corporate R&D Professionals'
Subscribe:
Subscribe to Clinical Genitourinary CancerAlready a print subscriber? Claim online access
Already an online subscriber? Sign in
Register: Create an account
Institutional Access: Sign in to ScienceDirect
References
- Global cancer observatory: cancer today. Lyon, France: International Agency for Research on Cancer.2020 (Accessed January 10, 2022. Published online)
- Epidemiology of Renal Cell Carcinoma.World J Oncol. 2020; 11: 79-87https://doi.org/10.14740/wjon1279
- Renal cell carcinoma: ESMO clinical practice guidelines for diagnosis, treatment and follow-up.Ann Oncol. 2019; 30: 706-720https://doi.org/10.1093/annonc/mdz056
- Avelumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.N Engl J Med. 2019; 380: 1103-1115https://doi.org/10.1056/NEJMoa1816047
Ljungberg B, Albiges L, Bedke J, et al. European Association of Urology guidelines on renal cell carcinoma, 2021 update. https://uroweb.org/guideline/renal-cell-carcinoma/. Accessed January 2022. Published online 2021.
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines In Oncology (NCCN Guidelines)—Kidney Cancer—Version 1.2022—July 1, 2021. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1440. Accessed January 2022. Published online 2021.
- Sequencing and combination of systemic therapy in metastatic renal cell carcinoma.Eur Urol Oncol. 2019; 2: 505-514https://doi.org/10.1016/j.euo.2019.06.022
- Individualizing systemic therapies in first line treatment and beyond for advanced renal cell carcinoma.Cancers (Basel). 2020; 12: E3750https://doi.org/10.3390/cancers12123750
- Sunitinib: ten years of successful clinical use and study in advanced renal cell carcinoma.The Oncol. 2017; 22: 41-52https://doi.org/10.1634/theoncologist.2016-0197
- Sunitinib for metastatic renal cell carcinoma: a systematic review and meta-analysis of real-world and clinical trials data.Target Oncol. 2019; 14: 405-416https://doi.org/10.1007/s11523-019-00653-5
- Nivolumab plus ipilimumab versus sunitinib in advanced renal-cell carcinoma.N Engl J Med. 2018; 378: 1277-1290https://doi.org/10.1056/NEJMoa1712126
- Pembrolizumab plus axitinib versus sunitinib for advanced renal-cell carcinoma.N Engl J Med. 2019; 380: 1116-1127https://doi.org/10.1056/NEJMoa1816714
- Nivolumab plus cabozantinib versus sunitinib for advanced renal-cell carcinoma.N Engl J Med. 2021; 384: 829-841https://doi.org/10.1056/NEJMoa2026982
- Real-world assessment of clinical outcomes among first-line sunitinib patients with clear cell metastatic renal cell carcinoma (mRCC) by the International mRCC database consortium risk group.Oncologist. 2020; 25: 422-430https://doi.org/10.1634/theoncologist.2019-0605
- Long-term response to sunitinib therapy for metastatic renal cell carcinoma.Clin Genitourin Cancer. 2013; 11: 297-302https://doi.org/10.1016/j.clgc.2013.04.001
- Long-term safety of sunitinib in metastatic renal cell carcinoma.European Urology. 2016; 69: 345-351https://doi.org/10.1016/j.eururo.2015.07.006
- Novel potential predictive markers of sunitinib outcomes in long-term responders versus primary refractory patients with metastatic clear-cell renal cell carcinoma.Oncotarget. 2017; 8: 30410-30421https://doi.org/10.18632/oncotarget.16494
- Real-world experience with sunitinib treatment in patients with metastatic renal cell carcinoma: clinical outcome according to risk score.Clin Genitourin Cancer. 2020; 18: e588-e597https://doi.org/10.1016/j.clgc.2020.02.013
- Sunitinib versus interferon alfa in metastatic renal-cell carcinoma.N Engl J Med. 2007; (Published online): 10
- Overall survival and updated results for sunitinib compared with interferon alfa in patients with metastatic renal cell carcinoma.JCO. 2009; 27: 3584-3590https://doi.org/10.1200/JCO.2008.20.1293
- Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.Br J Cancer. 2015; 113: 12-19https://doi.org/10.1038/bjc.2015.196
- Targeted therapies and complete responses in first line treatment of metastatic renal cell carcinoma. A meta-analysis of published trials.Cancer Treatment Reviews. 2014; 40: 271-275https://doi.org/10.1016/j.ctrv.2013.09.003
- Outcomes for patients with metastatic renal cell carcinoma achieving a complete response on targeted therapy: a registry-based analysis.European Urology. 2016; 70: 469-475https://doi.org/10.1016/j.eururo.2015.12.031
- Complete remission with tyrosine kinase inhibitors in renal cell carcinoma.JCO. 2012; 30: 482-487https://doi.org/10.1200/JCO.2011.37.2516
- Complete response and renal cell carcinoma in the immunotherapy era: the paradox of good news.Cancer Treat Rev. 2021; 99102239https://doi.org/10.1016/j.ctrv.2021.102239
- Outcome of treatment discontinuation in patients with metastatic renal cell carcinoma and no evidence of disease following targeted therapy with or without metastasectomy.Annals of Oncology. 2011; 22: 657-663https://doi.org/10.1093/annonc/mdq437
- Efficacy and safety of sunitinib in elderly patients with metastatic renal cell carcinoma.Br J Cancer. 2014; 110: 1125-1132https://doi.org/10.1038/bjc.2013.832
- [Specificity of the management of metastatic renal cancer in the older patient].Prog Urol. 2019; 29: 874-895https://doi.org/10.1016/j.purol.2019.08.272
- Clinical activity and molecular correlates of response to atezolizumab alone or in combination with bevacizumab versus sunitinib in renal cell carcinoma.Nat Med. 2018; 24: 749-757https://doi.org/10.1038/s41591-018-0053-3
- Molecular subsets in renal cancer determine outcome to checkpoint and angiogenesis blockade.Cancer Cell. 2020; 38: 803-817.e4https://doi.org/10.1016/j.ccell.2020.10.011
- Biomarker analysis from checkmate 214: nivolumab plus ipilimumab versus sunitinib in renal cell carcinoma.J Immunother Cancer. 2022; 10e004316https://doi.org/10.1136/jitc-2021-004316
- Immune checkpoint inhibitor combination therapy versus sunitinib as first-line treatment for favorable-IMDC-risk advanced renal cell carcinoma patients: a meta-analysis of randomized clinical trials.Biomedicines. 2022; 10: 577https://doi.org/10.3390/biomedicines10030577
- Disparities in the treatment and survival of metastatic renal cell carcinoma.Urology. 2021; (Published online November 19S0090-4295(21)01069-4)https://doi.org/10.1016/j.urology.2021.08.070
- First-line treatment of metastatic clear cell renal cell carcinoma: what are the most appropriate combination therapies?.Cancers (Basel). 2021; 13: 5548https://doi.org/10.3390/cancers13215548
- Outcomes of patients with metastatic clear-cell renal cell carcinoma treated with second-line VEGFR-TKI after first-line immune checkpoint inhibitors.European Journal of Cancer. 2019; 114: 67-75https://doi.org/10.1016/j.ejca.2019.04.003
- Combination therapy in renal cell carcinoma: the best choice for every patient?.Curr Oncol Rep. 2021; 23: 147https://doi.org/10.1007/s11912-021-01140-9
- Reviewing treatment options for advanced renal cell carcinoma: is there still a place for tyrosine kinase inhibitor (TKI) monotherapy?.Adv Ther. 2022; (Jan 13): 1-19https://doi.org/10.1007/s12325-021-02007-y
Article info
Publication history
Published online: December 02, 2022
Accepted:
November 29,
2022
Received in revised form:
November 28,
2022
Received:
October 10,
2022
Publication stage
In Press Journal Pre-ProofIdentification
Copyright
© 2022 Elsevier Inc. All rights reserved.
